US 12,469,580 B2
In silico discovery of effective antimicrobials
James Collins, Cambridge, MA (US); Regina Barzilay, Cambridge, MA (US); Jonathan Stokes, Cambridge, MA (US); Ian Andrews, Cambridge, MA (US); and Daniel Collins, Cambridge, MA (US)
Assigned to MASSACHUSETTS INSTITUTE OF TECHOLOGY, Cambridge, MA (US); and THE BROAD INSTITUTE, INC., Cambridge, MA (US)
Appl. No. 17/641,704
Filed by MASSACHUSETTS INSTITUTE OF TECHOLOGY, Cambridge, MA (US); and THE BROAD INSTITUTE, INC., Cambridge, MA (US)
PCT Filed Sep. 9, 2020, PCT No. PCT/US2020/049830
§ 371(c)(1), (2) Date Mar. 9, 2022,
PCT Pub. No. WO2021/050473, PCT Pub. Date Mar. 18, 2021.
Claims priority of provisional application 62/971,801, filed on Feb. 7, 2020.
Claims priority of provisional application 62/898,363, filed on Sep. 10, 2019.
Prior Publication US 2022/0310198 A1, Sep. 29, 2022
Int. Cl. G16B 15/30 (2019.01); A61K 31/433 (2006.01); A61K 31/655 (2006.01); A61P 31/04 (2006.01); G06N 3/126 (2023.01); G16B 5/20 (2019.01); G16B 35/20 (2019.01); G16B 40/20 (2019.01)
CPC G16B 15/30 (2019.02) [A61K 31/433 (2013.01); A61K 31/655 (2013.01); A61P 31/04 (2018.01); G06N 3/126 (2013.01); G16B 5/20 (2019.02); G16B 35/20 (2019.02); G16B 40/20 (2019.02)] 20 Claims
 
1. A pharmaceutical composition for treating a microbial infection in a subject comprising a therapeutically effective amount of:

OG Complex Work Unit Chemistry
5-[(5-nitro-1,3-thiazol-2-yl)sulfanyl]-1,3,4-thiadiazol-2-amine,
or a pharmaceutically acceptable salt or stereoisomer thereof, and a pharmaceutically acceptable carrier.